StockTipsArenaBeta

BUY Emcure Pharmaceuticals Limited — Vaishali Parekh, Prabhudas Lilladher

BUYEmcure Pharmaceuticals Limited
Emcure Pharmaceuticals share price target & all analyst calls

byVaishali Parekh, Prabhudas LilladherHorizon: NA (inferred 1–3 months)8 Jul 2026via NDTV Profit (Live)

Entry₹1,700Stated
Target₹2,200
Total upside +29.41% (call closed)
Stop lossNot given
Exit—No position was opened
ExpiredNA
Follow Vaishali Parekh for new calls(32% target hit, 31 closed calls)Get alertsWatch EMCURE for new buy/sell callsGet alertsSee 45 active Short-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 8 Oct 2026
16 supporting5 neutral3 opposing
Supports the BUY call (16)

Emcure Pharmaceuticals Limited (NSE: EMCURE) Reveals Strong Revenue Growth in FY26 Presentation

NewsGoogle News·28 Sept · 1w ago

(opens in new tab)

Emcure Pharmaceuticals reports over $1 billion operating revenue in FY26 with 16.6% growth

NewsGoogle News·25 Sept · 2w ago

(opens in new tab)

3 advisors have active long-term BUY calls on this stock

Advisor consensus · adjacent horizon·4 Sept · 1mo ago

Neutral / worth noting (5)

Market Trading Guide: Acme Solar, Bharat Dynamics among 5 stock recommendations for Wednesday

NewsEt-Markets·15 Sept · 3w ago

(opens in new tab)
Weighs against the BUY call (3)

Emcure Pharmaceuticals received income tax orders imposing an aggregate penalty of approximately Rs 57.74 crore for the financial years 2014-15 to 2020-21. The company is evaluating legal remedies.

NSE · Pendency of Litigation(s)/dispute(s) or the outcome impacting the Company·2 Oct · 5d ago

(opens in new tab)

Emcure Pharmaceuticals has received income tax orders imposing an aggregate penalty of approximately Rs 57.74 crore for the financial years 2014-15 to 2020-21. The company intends to appeal the orders

BSE · Company Update·2 Oct · 5d ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Emcure Pharmaceuticals

All analyst calls on Emcure Pharmaceuticals

More from Vaishali Parekh, Prabhudas Lilladher

Every call and its outcome